Panavance Therapeutics
  • Our Science
    • Pipeline
    • About Misetionamide
    • MOA
  • About
    • About Panavance
    • Leadership
    • Advisors & Collaborators
    • Contact Panavance
  • Resources
    • Publications
    • Brochures
    • Videos
    • Press Releases
    • Events
  • Participate

Let’s engage.

Innovative substance 2250 as a highly promising anti-neoplastic agent in malignant pancreatic carcinoma- in vitro and in vivo.

July 13, 2017 / 0 Minute Read

panavance therapeutics

  • Our Science
  • About
  • Resources
  • Participate
  • LinkedIn
  • Twitter
  • Facebook

+1.610.922.1910

Copyright © 2025 Panavance Therapeutics Inc.

  •  Our Science
    • Pipeline
    • About Misetionamide
    • MOA
  •  About
    • About Panavance
    • Leadership
    • Advisors & Collaborators
    • Contact Panavance
  •  Resources
    • Publications
    • Brochures
    • Videos
    • Press Releases
    • Events
  • Participate